229 related articles for article (PubMed ID: 31768803)
1. Comparison of the effects of valsartan plus activated vitamin D versus valsartan alone in IgA nephropathy with moderate proteinuria.
Xiaowei L; Bo W; Li L; Peng Z
Int Urol Nephrol; 2020 Jan; 52(1):129-136. PubMed ID: 31768803
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the efficacy and safety of TWHF in diabetic nephropathy patients with overt proteinuria and normal eGFR.
Xiong C; Li L; Bo W; Chen H; XiaoWei L; Hongbao L; Peng Z
J Formos Med Assoc; 2020 Mar; 119(3):685-692. PubMed ID: 31801679
[TBL] [Abstract][Full Text] [Related]
3. Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: a randomized controlled trial.
Liu LJ; Lv JC; Shi SF; Chen YQ; Zhang H; Wang HY
Am J Kidney Dis; 2012 Jan; 59(1):67-74. PubMed ID: 22019331
[TBL] [Abstract][Full Text] [Related]
4. Short-term anti-proteinuric effect of tacrolimus is not related to preservation of the glomerular filtration rate in IgA nephropathy: A 5-year follow-up study.
Yu MY; Kim YC; Koo HS; Chin HJ
PLoS One; 2017; 12(11):e0188375. PubMed ID: 29155873
[TBL] [Abstract][Full Text] [Related]
5. Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy.
Cheng G; Liu D; Margetts P; Liu L; Zhao Z; Liu Z; Tang L; Fang Y; Li H; Guo Y; Chen F; Liu F
Nephrology (Carlton); 2015 Feb; 20(2):77-84. PubMed ID: 25358874
[TBL] [Abstract][Full Text] [Related]
6. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study.
Li PK; Leung CB; Chow KM; Cheng YL; Fung SK; Mak SK; Tang AW; Wong TY; Yung CY; Yung JC; Yu AW; Szeto CC;
Am J Kidney Dis; 2006 May; 47(5):751-60. PubMed ID: 16632013
[TBL] [Abstract][Full Text] [Related]
7. Changes in Proteinuria and Side Effects of Corticosteroids Alone or in Combination with Azathioprine at Different Stages of IgA Nephropathy.
Sarcina C; Tinelli C; Ferrario F; Pani A; De Silvestri A; Scaini P; Del Vecchio L; Alberghini E; Buzzi L; Baragetti I; Pozzi C
Clin J Am Soc Nephrol; 2016 Jun; 11(6):973-981. PubMed ID: 27129712
[TBL] [Abstract][Full Text] [Related]
8. Effect of low-dose valsartan on proteinuria in normotensive immunoglobulin A nephropathy with minimal proteinuria: a randomized trial.
Jo YI; Na HY; Moon JY; Han SW; Yang DH; Lee SH; Park HC; Choi HY; Lim SD; Kie JH; Lee YK; Shin SK
Korean J Intern Med; 2016 Mar; 31(2):335-43. PubMed ID: 26874511
[TBL] [Abstract][Full Text] [Related]
9. Leflunomide plus low-dose prednisone in patients with progressive IgA nephropathy: a multicenter, prospective, randomized, open-labeled, and controlled trial.
Ni Z; Zhang Z; Yu Z; Lu F; Mei C; Ding X; Yuan W; Zhang W; Jiang G; Sun M; He L; Deng Y; Pang H; Qian J
Ren Fail; 2021 Dec; 43(1):1214-1221. PubMed ID: 34396911
[TBL] [Abstract][Full Text] [Related]
10. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
Manno C; Torres DD; Rossini M; Pesce F; Schena FP
Nephrol Dial Transplant; 2009 Dec; 24(12):3694-701. PubMed ID: 19628647
[TBL] [Abstract][Full Text] [Related]
11. A double-blind, randomized, placebo-controlled trial of combined calcitriol and ergocalciferol versus ergocalciferol alone in chronic kidney disease with proteinuria.
Susantitaphong P; Nakwan S; Peerapornratana S; Tiranathanagul K; Katavetin P; Srisawat N; Praditpornsilpa K; Eiam-Ong S
BMC Nephrol; 2017 Jan; 18(1):19. PubMed ID: 28088187
[TBL] [Abstract][Full Text] [Related]
12. Comparison of glucocorticoids alone and combined with cyclosporine a in patients with IgA nephropathy: a prospective randomized controlled trial.
Liu H; Xu X; Fang Y; Ji J; Zhang X; Yuan M; Liu C; Ding X
Intern Med; 2014; 53(7):675-81. PubMed ID: 24694475
[TBL] [Abstract][Full Text] [Related]
13. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
Song JH; Lee SW; Suh JH; Kim ES; Hong SB; Kim KA; Kim MJ
Clin Nephrol; 2003 Nov; 60(5):318-26. PubMed ID: 14640237
[TBL] [Abstract][Full Text] [Related]
14. Hydroxychloroquine alleviates persistent proteinuria in IgA nephropathy.
Gao R; Wu W; Wen Y; Li X
Int Urol Nephrol; 2017 Jul; 49(7):1233-1241. PubMed ID: 28349446
[TBL] [Abstract][Full Text] [Related]
15. Short-term effects of fish oil treatment on urinary excretion of high- and low-molecular weight proteins in patients with IgA nephropathy.
Branten AJ; Klasen IS; Wetzels JF
Clin Nephrol; 2002 Oct; 58(4):267-74. PubMed ID: 12400841
[TBL] [Abstract][Full Text] [Related]
16. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies.
Campbell R; Sangalli F; Perticucci E; Aros C; Viscarra C; Perna A; Remuzzi A; Bertocchi F; Fagiani L; Remuzzi G; Ruggenenti P
Kidney Int; 2003 Mar; 63(3):1094-103. PubMed ID: 12631093
[TBL] [Abstract][Full Text] [Related]
17. Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial.
Liu LJ; Yang YZ; Shi SF; Bao YF; Yang C; Zhu SN; Sui GL; Chen YQ; Lv JC; Zhang H
Am J Kidney Dis; 2019 Jul; 74(1):15-22. PubMed ID: 30922594
[TBL] [Abstract][Full Text] [Related]
18. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
Li S; Li JP
Trials; 2020 Jan; 21(1):31. PubMed ID: 31907076
[TBL] [Abstract][Full Text] [Related]
19. Comparison of steroid-pulse therapy and combined with mizoribine in IgA nephropathy: a randomized controlled trial.
Masutani K; Tsuchimoto A; Yamada T; Hirakawa M; Mitsuiki K; Katafuchi R; Hirakata H; Kitazono T; Tsuruya K;
Clin Exp Nephrol; 2016 Dec; 20(6):896-903. PubMed ID: 26758039
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of Mycophenolate Mofetil Among Patients With Progressive IgA Nephropathy: A Randomized Clinical Trial.
Hou FF; Xie D; Wang J; Xu X; Yang X; Ai J; Nie S; Liang M; Wang G; Jia N;
JAMA Netw Open; 2023 Feb; 6(2):e2254054. PubMed ID: 36745456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
